A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

NCT05473156 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Solid Tumors
Non Small Cell Lung Cancer (NSCLC)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: AP203
DRUG: AP203

Sponsor

AP Biosciences Inc.